Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

被引:878
作者
Hylek, Elaine M.
Evans-Molina, Carmella
Shea, Carol
Henault, Lori E.
Regan, Susan
机构
[1] Boston Univ, Sch Med, Boston Med Ctr,Dept Med, Res Unit,Sect Gen Internal Med, Boston, MA 02118 USA
[2] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA
[3] Univ Virginia, Dept Med, Charlottesville, VA USA
关键词
anticoagulants; atrial fibrillation; hemorrhage; stroke;
D O I
10.1161/CIRCULATIONAHA.106.653048
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Warfarin is effective in the prevention of stroke in atrial fibrillation but is under used in clinical care. Concerns exist that published rates of hemorrhage may not reflect real-world practice. Few patients >= 80 years of age were enrolled in trials, and studies of prevalent use largely reflect a warfarin-tolerant subset. We sought to define the tolerability of warfarin among an elderly inception cohort with atrial fibrillation. Methods and Results - Consecutive patients who started warfarin were identified from January 2001 to June 2003 and followed for 1 year. Patients had to be >= 65 years of age, have established care at the study institution, and have their warfarin managed on- site. Outcomes included major hemorrhage, time to termination of warfarin, and reason for discontinuation. Of 472 patients, 32% were >= 80 years of age, and 91% had >= 1 stroke risk factor. The cumulative incidence of major hemorrhage for patients >= 80 years of age was 13.1 per 100 person- years and 4.7 for those < 80 years of age (P = 0.009). The first 90 days of warfarin, age >= 80 years, and international normalized ratio (INR) >= 4.0 were associated with increased risk despite trial-level anticoagulation control. Within the first year, 26% of patients >= 80 years of age stopped taking warfarin. Perceived safety issues accounted for 81% of them. Rates of major hemorrhage and warfarin termination were highest among patients with CHADS(2) scores ( an acronym for congestive heart failure, hypertension, age >= 75, diabetes mellitus, and prior stroke or transient ischemic attack) of >= 3. Conclusions - Rates of hemorrhage derived from younger noninception cohorts underestimate the bleeding that occurs in practice. This finding coupled with the short-term tolerability of warfarin likely contributes to its underutilization. Stroke prevention among elderly patients with atrial fibrillation remains a challenging and pressing health concern.
引用
收藏
页码:2689 / 2696
页数:8
相关论文
共 48 条
  • [1] Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
  • [2] Albers GW, 2003, LANCET, V362, P1691
  • [3] Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack
    Arima, H
    Hart, RG
    Colman, S
    Chalmers, J
    Anderson, C
    Rodgers, A
    Woodward, M
    MacMahon, S
    Neal, B
    [J]. STROKE, 2005, 36 (10) : 2164 - 2169
  • [4] Inflammation as a risk factor for atrial fibrillation
    Aviles, RJ
    Martin, DO
    Apperson-Hansen, C
    Houghtaling, PL
    Rautaharju, P
    Kronmal, RA
    Tracy, RP
    Van Wagoner, DR
    Psaty, BM
    Lauer, MS
    Chung, MK
    [J]. CIRCULATION, 2003, 108 (24) : 3006 - 3010
  • [5] Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale
    Berg, AO
    Allan, JD
    Frame, PS
    Homer, CJ
    Johnson, MS
    Klein, JD
    Lieu, TA
    Mulrow, CD
    Orleans, CT
    Peipert, JF
    Pender, NJ
    Siu, AL
    Teutsch, SM
    Westhoff, C
    Woolf, SH
    [J]. ANNALS OF INTERNAL MEDICINE, 2002, 136 (02) : 157 - 160
  • [6] Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
    Beyth, RJ
    Quinn, LM
    Landefeld, CS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1998, 105 (02) : 91 - 99
  • [7] Blackshear JL, 1996, LANCET, V348, P633
  • [8] Why do patients with atrial fibrillation not receive warfarin?
    Bungard, TJ
    Ghali, WA
    Teo, KK
    McAlister, FA
    Tsuyuki, RT
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) : 41 - 46
  • [9] Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction
    Buresly, K
    Eisenberg, MJ
    Zhang, X
    Pilote, L
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (07) : 784 - 789
  • [10] Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
    Connolly, S.
    Pogue, J.
    Hart, R.
    Pfeffer, M.
    Hohnloser, S.
    Chrolavicius, S.
    Yusuf, S.
    [J]. LANCET, 2006, 367 (9526) : 1903 - 1912